查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046457

A型血友病A治療市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Hemophilia A Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 A 型血友病治療市場預計將經歷顯著成長，從 2025 年的 147.3 億美元成長到 2031 年的 214.4 億美元，複合年成長率為 6.46%。

該市場涵蓋多種治療方案，包括傳統的血漿衍生和重組VIII因子替代療法，以及創新治療方法和基因療法，所有這些療法都旨在解決遺傳性凝血因子缺乏症。推動該市場擴張的關鍵因素包括：遺傳性出血性疾病診斷率的提高、對有效減少出血事件的預防性治療方法的持續需求，以及發展中地區醫療保健服務的改善和有利的報銷政策。

市場概覽
預測期 2027-2031
市場規模：2025年 147.3億美元
市場規模：2031年 214.4億美元
複合年成長率：2026-2031年 6.46%
成長最快的細分市場 A型血友病
最大的市場 北美洲

儘管取得了這些令人鼓舞的進展，但仍有許多挑戰。特別是，許多新治療方法價格昂貴，且在開發中國家的可及性有限，這可能會阻礙整體市場成長。然而，全球在改善患者識別方面所做的努力正在取得進展。根據世界血友病聯盟（WFH）發布的《2024年全球年度調查報告》，來自創紀錄的135個國家的數據顯示，出血性疾病女性和女孩的識別率提高了9%，這凸顯了儘管存在經濟障礙，但在患者識別方面仍取得了穩步進展。

市場促進因素

血友病A治療市場的主要驅動力是長效（EHL）VIII因子濃縮製劑的進步。患者和臨床醫生越來越傾向於選擇這類治療方法，因為它們能夠提供持續的止血效果，同時減少注射次數，從而減輕慢性疾病的管理負擔。這項技術進步透過維持更高的因子谷濃度更長時間，提高了長期治療的依從性和臨床療效。這項轉變的商業性成功顯而易見。賽諾菲在2025年第三季新聞稿（2025年10月）中報告稱，銷售額成長了57.1%，達到10億歐元，這主要得益於新藥的上市，包括長效療法Altuviio。這表明市場對能夠改善患者生活品質並有效預防出血的最新替代療法給予了強力的支持。

同時，基因療法的商業化和監管核准為全球A型血友病治療市場開闢了一個變革性的新領域，並有望透過單次給藥實現功能性治癒。然而，這些促進因素的即時影響正受到許多重大障礙的限制，例如高昂的研發成本、複雜的報銷機制以及在合格的患者群體中謹慎的推廣步伐。 BioMarin公司的基因治療藥物Loctavian便是這種嚴峻商業性情勢的一個例子。根據Fierce Pharma於2025年2月發布的市場分析報告，該藥物2024年全年銷售額僅2,600萬美元，顯示其推廣速度低於預期。儘管基因治療領域面臨這些挑戰，但整體市場趨勢仍然強勁。根據羅氏公司發布的「2024會計年度業績報告」（2025年1月），其製藥部門的銷售額成長了8%，這主要得益於全球對現有血友病治療藥物的持續需求。

市場挑戰

全球A型血友病治療市場面臨的主要挑戰是新型治療方法的高昂費用及其在開發中國家的可近性有限。儘管包括重組產品和基因療法在內的先進治療方法療效顯著，但其高昂的價格使其不適用於缺乏完善醫療基礎設施和充足報銷體系的地區。這種經濟差距導致市場兩極化。預防性治療在高所得國家已成為標準治療方案，而開發中國家的患者往往只能在發作期間按需治療，甚至根本無法獲得必要的醫療服務。由於全球絕大多數患者居住在無法負擔這些昂貴藥物的地區，這種差距極大地限制了潛在市場規模。

因此，由於有益的治療方法無法在人口稠密、低收入地區有效商業化和推廣，整體市場擴張受到限制。根據世界血友病聯盟（WFH）於2024年發布的《2023年全球年度調查報告》，全球出血性疾病的檢出率僅成長了2%，而且由於資源限制，預計患者群體中仍有相當一部分未被診斷和治療。這種診斷和治療方面持續存在的差距（主要由經濟障礙造成）直接阻礙了全球血友病藥物生產商的銷售量成長潛力。

市場趨勢

重塑市場格局的根本趨勢之一是皮下注射雙特異性抗體的快速普及。這使得非因子替代療法逐漸成為標準治療方案，取代了傳統的靜脈輸注。此轉變的主要促進因素是雙特異性抗體能夠模擬活化因子VIII的功能，為患者提供穩定的止血效果，同時顯著減輕給藥負擔，並避免頻繁的靜脈穿刺。此類療法的商業性重要性日益凸顯，並在關鍵產品組合的調整中反映出來。羅氏發布的「2024會計年度業績報告」（2025年1月發布）強調，其主要促進因素，包括雙特異性抗體Hemlibra，創造了169億瑞士法郎的總合，證實了全球對這類微創預防性療法的強勁需求。

同時，新型再平衡療法和RNAi療法的研發正在拓展治療選擇，這些療法透過針對特定的抗凝血通路（例如組織因子途徑阻礙要素(TFPI) 和抗凝血酶）來恢復止血平衡。這些創新機制為更廣泛的患者群體提供了一種皮下預防性治療方案，無論是否存在阻礙要素，這些患者可能對標準替代療法或雙特異性抗體反應不佳。該領域的臨床療效檢驗正在快速推進，輝瑞公司於2025年6月發布的新聞稿公佈了3期BASIS試驗的主要結果。報告顯示，抗TFPI療法Hympavzi顯著改善了存在抑制劑患者的預後，使平均年出血發生率降低了1.4次。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球A型血友病治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（因子替代療法、非因子替代療法、基因療法）
    • 給藥途徑（靜脈注射、口服、鼻腔給藥）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美A型血友病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲A型血友病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區A型血友病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲A型血友病A治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲A型血友病A治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球A型血友病治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Takeda Pharmaceutical Company Limited
  • CSL Behring
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Bayer AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Octapharma AG
  • Grifols SA
  • BioMarin Pharmaceutical Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16872

The Global Hemophilia A Treatment Market is projected for significant growth, expanding from USD 14.73 Billion in 2025 to USD 21.44 Billion by 2031, representing a Compound Annual Growth Rate (CAGR) of 6.46%. This market encompasses various therapeutic options, including traditional plasma-based and recombinant Factor VIII replacement products, alongside innovative novel therapies and gene therapy, all designed to address the inherited deficiency of clotting proteins. Key factors driving this market expansion include increased diagnosis rates for genetic bleeding disorders, a sustained demand for preventive (prophylactic) treatment regimens that effectively reduce bleeding episodes, and enhanced healthcare accessibility coupled with favorable reimbursement policies in developing regions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 14.73 Billion
Market Size 2031USD 21.44 Billion
CAGR 2026-20316.46%
Fastest Growing SegmentHaemophilia A
Largest MarketNorth America

Despite these encouraging developments, substantial challenges persist, notably the prohibitive cost of many novel therapies and their limited availability in developing nations, which could hinder overall market growth. Nonetheless, global efforts to improve patient identification are showing progress; according to the 'World Federation of Hemophilia's 'Report on the Annual Global Survey 2024' from 2025, data from a record 135 countries indicated a 9% rise in the identification of women and girls with bleeding disorders, highlighting ongoing strides in patient identification despite economic barriers.

Market Driver

A primary driver propelling the Hemophilia A treatment market is the advancement of Extended Half-Life (EHL) Factor VIII concentrates. Both patients and clinicians increasingly favor these regimens due to their ability to provide sustained hemostatic protection with fewer injections, thereby easing the burden of chronic disease management. This technological evolution improves long-term treatment adherence and clinical outcomes by maintaining higher factor trough levels for extended periods. The commercial success of this shift is evident; Sanofi reported in its 'Q3 2025 Press Release' (October 2025) that revenue from new pharmaceutical launches, particularly spearheaded by the EHL therapy Altuviiio, surged by 57.1% to €1.0 billion, demonstrating a strong market preference for modern replacement options that enhance patient quality of life and prevent bleeding effectively.

Simultaneously, the commercialization and regulatory approval of gene therapies represent a transformative frontier for the Global Hemophilia A Treatment Market, holding the promise of a functional cure through a single administration. However, the immediate impact of this driver is tempered by significant obstacles, including high development costs, complex reimbursement structures, and a cautious rate of adoption among eligible patient populations. This challenging commercial landscape was exemplified by BioMarin's gene therapy Roctavian, which generated only $26 million in sales for the full year 2024, as noted in a Fierce Pharma market analysis report from February 2025, reflecting slower-than-anticipated uptake. Despite these specific hurdles within the gene therapy segment, the broader market trajectory remains positive; Roche's '2024 Annual Results' (January 2025) showed an 8% sales growth in its Pharmaceuticals Division, largely driven by the ongoing global demand for established hemophilia treatments.

Market Challenge

A significant challenge confronting the Global Hemophilia A Treatment Market is the exorbitant cost associated with novel therapies and their restricted availability in developing nations. While advanced treatments, including recombinant products and gene therapy, offer superior outcomes, their high price points render them inaccessible in regions lacking robust healthcare infrastructure and adequate reimbursement frameworks. This economic disparity fosters a bifurcated market: prophylactic regimens are standard in high-income countries, whereas patients in developing nations often rely on episodic, on-demand treatment or face a complete absence of access to necessary care. This divide substantially limits the total addressable market, as the majority of the global patient population resides in areas unable to afford these premium therapeutics.

Consequently, the market's overall expansion is constrained by the inability to effectively commercialize and distribute beneficial treatments in populous low-income regions. The 'World Federation of Hemophilia's 'Report on the Annual Global Survey 2023' from 2024 indicated that the global identification of individuals with bleeding disorders increased by merely 2%, leaving a considerable portion of the anticipated patient population undiagnosed and untreated due to resource limitations. This persistent gap in diagnosis and access, largely driven by financial barriers, directly impedes the potential volume growth for manufacturers of hemophilia therapeutics worldwide.

Market Trends

A fundamental trend reshaping the market is the rapid adoption of subcutaneous bispecific antibodies, which are establishing non-factor replacement therapies as a preferred standard of care over conventional intravenous infusions. This shift is primarily driven by the capacity of bispecific agents to mimic the function of activated Factor VIII, providing patients with steady-state hemostasis and a significantly reduced burden of administration, avoiding the need for frequent venous access. The growing commercial prominence of this therapeutic class is increasingly evident in major portfolio adjustments; Roche's '2024 Annual Results' (January 2025) highlighted that its top growth drivers, including the bispecific antibody Hemlibra, collectively generated total sales of CHF 16.9 billion, underscoring robust global demand for these less invasive prophylactic options.

Concurrently, the development of novel rebalancing and RNAi therapeutics is expanding treatment horizons by targeting specific anticoagulation pathways, such as tissue factor pathway inhibitor (TFPI) and antithrombin, to restore hemostatic balance. These innovative mechanisms offer a subcutaneous prophylactic alternative for a broader range of patients, including those with or without inhibitors who may not adequately respond to standard replacement therapies or bispecific antibodies. This segment is experiencing rapid clinical validation; Pfizer's 'Press Release' (June 2025) reported topline results from the Phase 3 BASIS trial, indicating that the anti-TFPI therapy Hympavzi significantly improved outcomes for patients in the inhibitor cohort, reducing the mean annualized bleeding rate to 1.4 events per year.

Key Market Players

  • Takeda Pharmaceutical Company Limited
  • CSL Behring
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Bayer AG
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Octapharma AG
  • Grifols S.A.
  • BioMarin Pharmaceutical Inc

Report Scope

In this report, the Global Hemophilia A Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemophilia A Treatment Market, By Treatment Type

  • Factor Replacement Therapy
  • Non-Factor Replacement Therapies
  • Gene Therapy

Hemophilia A Treatment Market, By Route of Administration

  • Intravenous
  • Oral
  • Nasal

Hemophilia A Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hemophilia A Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemophilia A Treatment Market.

Available Customizations:

Global Hemophilia A Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hemophilia A Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Factor Replacement Therapy, Non-Factor Replacement Therapies, Gene Therapy)
    • 5.2.2. By Route of Administration (Intravenous, Oral, Nasal)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Hemophilia A Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hemophilia A Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Hemophilia A Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Hemophilia A Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Hemophilia A Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hemophilia A Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Hemophilia A Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Hemophilia A Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Hemophilia A Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Hemophilia A Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Hemophilia A Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Hemophilia A Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Hemophilia A Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Hemophilia A Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Hemophilia A Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Hemophilia A Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Hemophilia A Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Hemophilia A Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Hemophilia A Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Hemophilia A Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Hemophilia A Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hemophilia A Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Hemophilia A Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Hemophilia A Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Hemophilia A Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Takeda Pharmaceutical Company Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. CSL Behring
  • 15.3. Pfizer Inc.
  • 15.4. Novo Nordisk A/S
  • 15.5. Bayer AG
  • 15.6. Sanofi S.A.
  • 15.7. F. Hoffmann-La Roche Ltd.
  • 15.8. Octapharma AG
  • 15.9. Grifols S.A.
  • 15.10. BioMarin Pharmaceutical Inc

16. Strategic Recommendations

17. About Us & Disclaimer